SEI Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$714K Buy
49,913
+33,249
+200% +$433K ﹤0.01% 2470
2026
Q2
$222K Buy
16,664
+3,802
+30% +$37K ﹤0.01% 3007
2026
Q1
$120K Buy
12,862
+1,050
+9% +$9.14K ﹤0.01% 3068
2025
Q4
$88.6K Buy
11,812
+139
+1% +$1.41K ﹤0.01% 3028
2025
Q3
$101K Sell
11,673
-16,862
-59% -$101K ﹤0.01% 2714
2025
Q2
$106K Buy
28,535
+103
+0.4% +$362 ﹤0.01% 2682
2025
Q1
$91.8K Buy
+28,432
New +$134K ﹤0.01% 2612
2024
Q2
– Sell
-15,818
Closed -$504K – 2673
2024
Q1
$504K Buy
+15,818
New +$404K ﹤0.01% 2113

Other funds holding FDMT

SEI Investments's FDMT Position: Q3 2026 in Review

SEI Investments increased its 4D Molecular Therapeutics (FDMT) stake by 200% in Q3 2026, buying an estimated $433K and bringing the position to 49,913 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

SEI Investments first reported a position in FDMT in Q1 2024 and has held it in 8 quarters since. 162 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • SEI Investments held 49,913 shares of 4D Molecular Therapeutics worth $714K as of Q3 2026.
  • SEI Investments bought 33,249 4D Molecular Therapeutics shares in Q3 2026, an estimated $433K.
  • 4D Molecular Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #2470 holding.
  • SEI Investments first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 162 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.